Quick Answer
Protalix BioTherapeutics, Inc. reported Research And Development Expense of $19.57 million for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +50.9% in Research And Development Expense from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $6.32 million | Q1 2011: $10.56 million | Q2 2011: $8.77 million | Q3 2011: $9.34 million | Q1 2012: $8.85 million | Q2 2012: $10.54 million | Q3 2012: $8.33 million | Q1 2013: $7.75 million | Q2 2013: $7.99 million | Q3 2013: $7.72 million | Q1 2014: $8.15 million | Q2 2014: $7.08 million | Q3 2014: $8.05 million | Q1 2015: $6.10 million | Q2 2015: $6.02 million | Q3 2015: $5.07 million | Q1 2016: $7.33 million | Q2 2016: $10.01 million | Q3 2016: $6.35 million | Q1 2017: $5.97 million | Q2 2017: $9.30 million | Q3 2017: $7.12 million | Q1 2018: $7.29 million | Q2 2018: $7.48 million | Q3 2018: $10.07 million | Q1 2019: $11.70 million | Q2 2019: $13.32 million | Q3 2019: $10.00 million | Q1 2020: $10.34 million | Q2 2020: $9.19 million | Q3 2020: $7.69 million | Q1 2021: $7.12 million | Q2 2021: $7.69 million | Q3 2021: $7.28 million | Q1 2022: $8.77 million | Q2 2022: $7.58 million | Q3 2022: $7.39 million | Q1 2023: $5.85 million | Q2 2023: $4.48 million | Q3 2023: $3.67 million | Q1 2024: $2.89 million | Q2 2024: $2.96 million | Q3 2024: $3.00 million | Q1 2025: $3.48 million | Q2 2025: $5.99 million | Q3 2025: $4.47 million.
- Over the full 17 years of available data (2009 to 2025), Protalix BioTherapeutics, Inc.'s Research And Development Expense has declined by 28.6%.
- Historical annual values: Fiscal year 2025: $19.57 million | Fiscal year 2024: $12.97 million | Fiscal year 2023: $17.09 million | Fiscal year 2022: $29.35 million | Fiscal year 2021: $29.73 million | Fiscal year 2020: $38.17 million | Fiscal year 2019: $44.62 million | Fiscal year 2018: $33.33 million | Fiscal year 2017: $32.17 million | Fiscal year 2016: $30.41 million | Fiscal year 2015: $24.89 million | Fiscal year 2014: $27.35 million | Fiscal year 2013: $29.23 million | Fiscal year 2012: $36.67 million | Fiscal year 2011: $37.82 million | Fiscal year 2010: $37.69 million | Fiscal year 2009: $27.39 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: